Trial Profile

Tocilizumab (Actemra) Plus a Short Prednisone Taper for Giant Cell (GCA)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prednisone (Primary) ; Tocilizumab (Primary)
Indications Giant cell arteritis
Focus Therapeutic Use

Most Recent Events

04 Jun 2022 Status changed from recruiting to completed.
04 Jun 2022 Results assessing the efficacy and safety of tocilizumab (TCZ) in combination with 2 months of prednisone in a group of patients with GCA presented at the 23rd Annual Congress of the European League Against Rheumatism
24 Feb 2020 Planned primary completion date changed from 1 Dec 2021 to 25 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com